Setting Realistic Expectations

Before getting into specific options, it's worth being clear about what "works" means in this context. No non-hormonal treatment matches MHT's efficacy for vasomotor symptoms — a 75–87% reduction in hot flash frequency and severity is simply not achievable without systemic estrogen. The best non-hormonal alternatives reduce vasomotor symptoms by roughly 40–65%, which is meaningful but not equivalent.[1] For women choosing a non-hormonal path, the goal is the best available reduction in symptom burden, not the same outcome MHT would provide.

Genitourinary symptoms — vaginal dryness, pain with intercourse, urinary urgency — are a separate story. These are addressable with local treatment that stays largely outside the systemic hormone conversation, which is why vaginal estrogen gets its own dedicated section below.

Non-Hormonal Options for Vasomotor Symptoms

SSRIs and SNRIs — My First-Line Recommendation

Efficacy: 40–65% reduction Generic options available — cost-effective

Certain antidepressants reduce hot flash frequency through central mechanisms — they modulate the same neurotransmitter pathways involved in temperature regulation. Low-dose venlafaxine (an SNRI) is my usual starting point: it has strong evidence, is inexpensive as a generic, and works well when there's also a mood component. Paroxetine (an SSRI) at 7.5 mg is the only agent with FDA approval specifically for vasomotor symptoms (brand name Brisdelle); other agents are used off-label at doses lower than their antidepressant doses.[1]

Important — tamoxifen interaction: Paroxetine significantly inhibits the enzyme that converts tamoxifen to its active form, reducing tamoxifen's effectiveness. Women on tamoxifen should never take paroxetine — venlafaxine is the right choice in that situation.[1]

Important — do not stop SNRIs abruptly: Venlafaxine and other SNRIs can cause significant discontinuation symptoms — dizziness, nausea, electric-shock sensations, and anxiety — if stopped suddenly. When it's time to come off these medications, the dose should be tapered gradually over several weeks. This applies even at the low doses used for vasomotor symptoms.

Side effects at low doses are generally mild — nausea, sleep disturbance, and sexual side effects are less common than at full antidepressant doses but still occur. The mood benefit is a real clinical plus for women who are also experiencing depression or anxiety during the transition.

Fezolinetant (Veozah)

Efficacy: ~50% reduction in frequency FDA-approved 2023 — brand only, significantly more expensive

Fezolinetant is the newest non-hormonal option and the most mechanistically targeted — it works by blocking neurokinin B receptors in the hypothalamus, which are directly involved in triggering hot flashes. This makes it more precise than SSRIs, which affect hot flashes as a secondary effect.[1]

Clinical trials showed approximately 50% reduction in hot flash frequency with meaningful improvements in severity and sleep. It has no hormonal activity and no sexual side effects. The main concern is liver enzyme elevation in a small number of patients — liver function is checked before starting and monitored periodically.[1]

In practice, I reach for fezolinetant when venlafaxine and gabapentin haven't provided adequate relief or aren't tolerated. The efficacy data is similar to SSRIs/SNRIs, and the cost difference — which can be substantial — is a real consideration for long-term use. When generic options work as well, they're usually the right starting point.

Gabapentin — My Second Reach for Nighttime Symptoms

Efficacy: ~45% reduction Generic — cost-effective

Gabapentin is inexpensive, widely available as a generic, and particularly useful when hot flashes are most disruptive at night. The sedating side effect that limits daytime use actually becomes an advantage when the primary goal is better sleep. I reach for it early in the prescribing sequence — ahead of fezolinetant — because the cost and efficacy profile makes it a practical first or second choice rather than a fallback.[1]

It requires dose titration to minimize dizziness and sedation and is used off-label for this indication. For women whose symptoms are primarily daytime hot flashes, it's less ideal than venlafaxine — but for the patient who is waking multiple times a night, it's often the better fit.

Oxybutynin

Efficacy: modest — emerging evidence

Oxybutynin — better known as a bladder medication — has shown modest benefit for hot flashes in small trials. The mechanism isn't fully understood. It's occasionally used off-label when other options have failed or aren't tolerated, but the evidence base is thinner than for SSRIs or fezolinetant and anticholinergic side effects (dry mouth, constipation, cognitive effects) limit its appeal, particularly in older patients.

Clonidine

Efficacy: modest, inconsistent

Clonidine, a blood pressure medication, modestly reduces hot flash frequency in some patients. Evidence is inconsistent and effect sizes are smaller than other options. I don't recommend it in my practice — the risk of rebound hypertension and rebound anxiety on discontinuation is a meaningful clinical problem, and the other options available work better with fewer risks. It's worth knowing it exists, but it's not a tool I reach for.

📊 The Evidence — Non-Hormonal Options in Context A 2022 JAMA review of management strategies found that SSRIs and SNRIs reduce vasomotor symptom frequency by 40–65%, fezolinetant by approximately 50%, and gabapentin by approximately 45% — all meaningfully less than the 75–87% reduction seen with systemic estrogen.[1] None of these options address genitourinary symptoms, bone density loss, or the cardiovascular changes associated with estrogen withdrawal. For women who cannot take systemic MHT, these are real and valuable options — but the gap in efficacy compared to MHT is worth naming honestly rather than minimizing.
My Synthesis My general preference across medicine is to start with affordable, proven generic options before moving to newer, more expensive medications — especially when the efficacy data is similar. For vasomotor symptoms that aren't going to be treated with MHT, that means low-dose venlafaxine first for most patients, particularly those with any mood component. Gabapentin comes early in the sequence for women whose primary problem is nighttime symptoms disrupting sleep. I avoid paroxetine entirely in women on tamoxifen — venlafaxine is safer in that situation. I reserve fezolinetant for women who haven't responded adequately to the generic options or can't tolerate them — the mechanism is elegant and the evidence is good, but its efficacy is roughly comparable to SNRI therapy rather than superior to it, and the cost difference is substantial. I don't use clonidine — the rebound hypertension and anxiety risk on discontinuation makes it a poor trade for a symptom that has better options. I'm always transparent with patients about the efficacy gap versus MHT — non-hormonal options genuinely don't work as well, and patients deserve to know that upfront rather than discover it after several months.

What About Lifestyle Measures?

Patients frequently ask about dietary changes, supplements, and lifestyle modifications. The evidence varies considerably — a few non-pharmacologic approaches have real support, while most popular remedies don't hold up to scrutiny.

What Actually Has Evidence

Cognitive behavioral therapy (CBT) is the non-pharmacologic approach with the strongest evidence. A 2022 meta-analysis of 14 randomized trials found that CBT significantly reduced perceived hot flash severity, night sweats, depression, anxiety, and fatigue compared to controls — with benefits sustained long-term.[2] Notably, CBT reduces the distress and interference caused by hot flashes more than the raw frequency, which matters enormously for quality of life. It can be delivered as group sessions, self-help books, telephone sessions, or online, making it accessible without specialist referral.[2]

Clinical hypnosis has two small but well-designed randomized trials behind it. The North American Menopause Society cites a 74% reduction in subjective hot flash frequency at 12 weeks with hypnosis versus 17% in controls — a striking difference, though from small trials.[3] It also improved sleep quality and reduced symptom interference. Hypnosis can be delivered by a trained provider or accessed via smartphone app. For women who are interested and have access, it's worth recommending.

Keeping cool is simple, free, and genuinely helpful. Layered clothing, a fan, and a cool sleeping environment reduce the impact of hot flashes and night sweats significantly. Several of my patients have found cooling blankets — blankets with moisture-wicking or temperature-regulating materials — particularly helpful for nighttime symptoms, and I routinely mention them. These aren't glamorous interventions, but they work and carry no risk.

Avoiding common triggers — caffeine, alcohol, spicy food, and hot beverages — reduces hot flash frequency for some women. The effect is modest and varies by individual, but since these changes carry no downside they're reasonable to try alongside other treatments.

What Doesn't Have Good Evidence

Exercise, yoga, mindfulness, biofeedback, and paced breathing are safe and support general wellbeing — but have not been found effective specifically for reducing vasomotor symptom frequency.[4][5] Acupuncture is no better than sham acupuncture for hot flash frequency in head-to-head trials, though it outperforms doing nothing — suggesting a placebo effect rather than a specific mechanism.[6]

Herbal and supplement approaches — black cohosh, soy isoflavones, ginseng, probiotics, and others — have inconsistent or negative evidence and are not recommended as evidence-based treatments.[5] Black cohosh has the most trial data of the group and one meta-analysis showing modest benefit, but the lack of regulatory oversight of supplement quality and the availability of better-studied options makes it a poor first choice.[1] Phytoestrogens found in soy and red clover are safe for most women and reasonable to try, but the effect is considerably smaller than any pharmacologic option and the evidence is heterogeneous.[1]

Vaginal Estrogen: The Most Underused Treatment in Menopause

A special case worth understanding on its own terms

Vaginal estrogen is local treatment — applied directly to vaginal and urinary tissue, absorbed minimally into the bloodstream, and carrying a safety profile that is fundamentally different from systemic hormone therapy. It belongs in a different conversation than MHT, and it's appropriate for a much wider group of women — including many who have been told they cannot use hormones at all.

Genitourinary syndrome of menopause (GSM) — the constellation of vaginal dryness, atrophy, pain with intercourse, urinary urgency, and recurrent urinary tract infections that develops with estrogen loss — affects a large proportion of postmenopausal women and, unlike vasomotor symptoms, does not improve on its own with time. It worsens progressively without treatment. Vaginal estrogen directly addresses this by restoring local estrogen to vaginal and urethral tissue.

The Safety Profile — Including the FDA Update

For years, vaginal estrogen products carried the same FDA boxed warning as systemic MHT — a blanket class label applied because they were categorized together. That warning has now been removed specifically for vaginal estrogen, with the FDA acknowledging that local vaginal estrogen has a distinct safety profile from systemic hormone therapy.[3][4]

📊 The Evidence — Vaginal Estrogen Safety

Licensed doses of vaginal estrogen do not raise systemic estradiol levels above the normal postmenopausal range with long-term use. There is no evidence of increased risk of coronary heart disease, stroke, blood clots, endometrial cancer, or breast cancer with local vaginal estrogen in the general postmenopausal population.[5][6] A progestogen is not required for endometrial protection with low-dose vaginal estrogen — the systemic absorption is too low to stimulate the endometrium meaningfully.[2][6]

For women with a history of breast cancer — including those on tamoxifen — the data are more reassuring than many providers realize. A 2025 systematic review and meta-analysis of over 59,000 breast cancer patients found that vaginal estrogen use was not associated with increased breast cancer recurrence (OR 0.48), breast cancer-specific mortality (OR 0.60), or overall mortality (OR 0.46).[7] A large UK cohort study of 49,237 women with breast cancer similarly found no increase in breast cancer-specific mortality (HR 0.77).[8]

The one area of caution is women on aromatase inhibitors (AIs) rather than tamoxifen. A Danish cohort study found no overall increase in recurrence with vaginal estrogen, but a subgroup of AI users showed a modestly increased recurrence risk (RR 1.39).[9] This is biologically plausible — tamoxifen blocks estrogen at the receptor level, providing protection even against small amounts of absorbed estrogen, while AIs do not. For AI users considering vaginal estrogen, this should be a shared decision involving their oncologist.[2]

Formulations

Vaginal estrogen comes in several forms — creams, tablets or inserts, and rings. My default recommendation is the cream: it's inexpensive, widely available at any pharmacy, and works well. Tablets and rings tend to produce more consistent systemic absorption levels and are sometimes cited as preferable on that basis, but for most patients the cream is the practical and affordable starting point. All formulations provide meaningful local symptom relief; the choice ultimately comes down to patient preference, cost, and convenience. Vaginal DHEA (prasterone) and oral ospemifene are non-estrogen alternatives that improve GSM through different mechanisms and are appropriate for women who prefer to avoid even local estrogen.[1]

My Synthesis Vaginal estrogen is one of the treatments I recommend most enthusiastically in older patients and in women who cannot take systemic MHT — and one of the most frequently underused. The FDA boxed warning removal is significant because it removes a barrier that was never scientifically justified for local treatment. A woman who has been told she "can't use hormones" because of a breast cancer history, cardiovascular history, or provider caution about systemic MHT may well be an excellent candidate for vaginal estrogen — the safety data simply don't show the same concerns, and the genitourinary benefit is real and clinically meaningful.

For women on aromatase inhibitors, I have this conversation carefully and involve oncology when the patient wants to proceed. For women on tamoxifen, the recurrence data is reassuring enough that I'm comfortable offering vaginal estrogen with appropriate counseling. The quality-of-life impact of untreated GSM — including pain, avoidance of intimacy, and recurrent infections — is substantial, and the reflexive avoidance of local estrogen in breast cancer survivors has caused real harm by leaving those symptoms untreated.